Meta-analysis supports the diagnostic value of GP73 in primary liver cancer

2015 ◽  
Vol 39 (5) ◽  
pp. e71-e72 ◽  
Author(s):  
Rong Liang ◽  
Xin-yu Chen ◽  
Lian-ying Ge ◽  
Sheng-xin Huang ◽  
Xiao-ling Luo
Keyword(s):  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Meta Analysis ◽  
Diagnostic Value

scholarly journals The prognostic significance of pretreatment serum γ-glutamyltranspeptidase in primary liver cancer: a meta-analysis and systematic review

2018 ◽  
Vol 38 (6) ◽  
Author(s):  
Yang Ou ◽  
Junwei Huang ◽  
Liping Yang
Keyword(s):  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Prognostic Impact ◽  
Free Survival ◽  
Effect Measure ◽  
Pretreatment Serum ◽  
Disease Free

Aim: To assess the prognostic value of the pretreatment serum γ-glutamyltranspeptidase (GGT) level in patients with primary liver cancer (PLC). Methods: Relevant studies were systematically searched online on Web of Science, PubMed, and Embase databases published until 9 October 2018. The end points were overall survival (OS), recurrence-free survival (RFS), and disease-free survival (DFS). Meta-analysis was conducted using hazard ratio (HR), and its 95% confidence interval (CI) as effect measure. Results: A total of 33 eligible studies with 9238 patients with PLC were included in this meta-analysis. The synthesized analysis showed that that higher serum GGT level was significantly related to poorer OS (HR: 1.79, 95% CI: 1.66–1.93, P<0.01), RFS (HR: 1.60, 95% CI: 1.46–1.77, P<0.01), and DFS (HR: 1.52, 95% CI: 1.33–1.73, P<0.01) of patients with PLC. Subgroup analyses demonstrated that the negative prognostic impact of higher serum GGT level on OS and RFS was still of significance regardless of ethnicity, pathological type, sample size, cut-off value, first-line treatment, and analysis type. Conclusion: The pretreatment serum GGT might be a predictive factor of poor prognosis for PLC patients.

scholarly journals Diagnostic value of combined detection of angiopoietin-2 and Golgi protein 73 in primary liver cancer

2015 ◽  
Vol 23 (25) ◽  
pp. 4032
Author(s):  
Wen-Li Sai ◽  
Wen Chen ◽  
Deng-Fu Yao ◽  
Li-Wei Qiu ◽  
Wei Wu ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Diagnostic Value ◽  
Golgi Protein ◽  
Angiopoietin 2 ◽  
Combined Detection

scholarly journals Meta-analysis of studies using statins as a reducer for primary liver cancer risk

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Guo-Chao Zhong ◽  
Yan Liu ◽  
Yuan-Yuan Ye ◽  
Fa-Bao Hao ◽  
Kang Wang ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cancer Risk ◽  
Primary Liver Cancer ◽  
Meta Analysis

The association between metabolic syndrome and primary liver cancer: A meta-analysis.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 175-175
Author(s):  
Raxitkumar Jinjuvadia ◽  
Basile M. Njei ◽  
Ivo C. Ditah
Keyword(s):  
Metabolic Syndrome ◽  
Liver Cancer ◽  
Publication Bias ◽  
Primary Liver Cancer ◽  
Meta Analysis ◽  
Case Control ◽  
Quality Data ◽  
Cochrane Library ◽  
Combined Analysis ◽  
Funnel Plot

175 Background: The Metabolic syndrome (MetS) and/or its individual components have been liked to the development of cancer. Recent studies have suggested a similar link to Primary Liver Cancer (PLC). The mechanism for the development of cancer in this group of patients remains unclear. The aim of this study was to evaluate the direction and magnitude of the association between the MetS and PLC. Methods: Two reviewers independently conducted a systemic search of the PubMed, OvidSP and Cochrane Library databases from January 1980 to July 2011. Search terms included ‘Metabolic syndrome’, ‘insulin resistance syndrome’ combined with ‘hepatocellular carcinoma’, ‘liver cancer’ and ‘GI malignancy’. No language restriction was applied to the search. Only studies reporting an effect measure for the association between MetS and PLC were eligible for inclusion. Metabolic syndrome was defined according to NCEP/ATP III, IDF, AHA and WHO guidelines. Identified articles were reviewed for additional references. Combined analysis including all studies was done using a random effects model. Publication bias was assessed using the Begg and Egger’s tests, with a visual inspection of funnel plot. All analyses were performed using Comprehensive Meta-Analysis version 2 software. Results: Five studies (4 cohort and 1 case-control) including 863,714 participants were included in the analysis. The age range of participants was between 20 and 88 years. The combined analysis showed an overall 74% increase risk of PLC in cases with MetS (RR: 1.74, 95% CI: 1.36-2.24). After excluding the single case-control study from analysis, the overall risk ratio remained statistically significant (RR: 1.62, 95% CI: 1.22-2.15). Funnel plot inspection, Begg and Egger’s tests showed no evidence of publication bias, whether in the combined or subgroup analysis. Conclusions: Though studies are scarce, currently available epidemiologic data is suggestive of positive association with significantly higher risk of liver cancer among patients with metabolic syndrome. More studies are required before reaching conclusive statement regarding this association. Further better-designed studies with good quality data with definitely aid in strengthening this association.

Abstract 2300: Pesticides and primary liver cancer: A systematic review and meta-analysis

2017 ◽  
Author(s):  
Hamdi Abdi ◽  
Jennifer Lee ◽  
Gary Ellison ◽  
Gabriel Lai ◽  
Tram Lam
Keyword(s):  
Systematic Review ◽  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Meta Analysis

scholarly journals Serum Biomarkers of Iron Status and Risk of Primary Liver Cancer: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 71 (8) ◽  
pp. 1365-1373 ◽  
Author(s):  
Kim Tu Tran ◽  
Helen G. Coleman ◽  
Robert Stephen McCain ◽  
Chris R. Cardwell
Keyword(s):  
Systematic Review ◽  
Liver Cancer ◽  
Iron Status ◽  
Primary Liver Cancer ◽  
Meta Analysis ◽  
Serum Biomarkers
Sign in / Sign up

Export Citation Format

Share Document